CompletedInterventionalPhase 3Updated Dec 16, 2013
Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. | NCT01155999 | Trialant
CompletedInterventionalPhase 3Updated Oct 29, 2014
Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.
ClinicalTrials.gov ID
NCT01155999
Lead Sponsor
Laboratoires TheaINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
286Actual
Last Update Posted
Oct 29, 2014Estimated
Start Date
Dec 2008
Primary Completion Date
Feb 2011Actual
Completion Date
Feb 2011Actual
Brief Summary
Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.